CBX7 and neoplasm: Other DNMT inhibitors that have not yet progressed to clinical trials include chromobox 7 (CBX7), which has been shown to cause tumour suppression in vitro [62], and CM-272, which can cause tumour and metastasis regression in in vivo transgenic mouse models [63].